<ѻýҕl>WHO Links Sweetener to Cancer; Younger-Age CRC Risk; PCOS and Ovarian Cancerѻýҕl> News, features, and commentary about cancer-related issues Jun 29, 2023
<ѻýҕl>New Agents for Relapsed/Refractory Myeloma Impress in Early-Stage Clinical Trialsѻýҕl> High rates of deep, durable response with bispecific antibody, rapidly produced CAR T-cell agents Jun 05, 2023
<ѻýҕl>CAR-T Tops Standard Care in Heavily Pretreated Lenalidomide-Refractory Myelomaѻýҕl> Ciltacabtagene autoleucel improved progression-free survival versus two standard triplets Jun 05, 2023
<ѻýҕl>Novel Antibody Induces Durable Responses in Heavily Pretreated Myelomaѻýҕl> Overall response rate of 90% in patients who received highest doses of REGN5459 Apr 18, 2023
<ѻýҕl>Novel 'Off the Shelf' CAR-T Product Shows Promise in Myelomaѻýҕl> Researchers say safety, efficacy of ALLO-715 comparable to autologous anti-BCMA products Feb 02, 2023
<ѻýҕl>Off-the-Shelf T-Cell Therapy Effective Against Viral Infections After Allo-HCTѻýҕl> Produced an antiviral response in 95% of patients with six different types of infection Jan 13, 2023
<ѻýҕl>Talquetamab Offers New Hope in Relapsed/Refractory Multiple Myelomaѻýҕl> Bispecific antibody achieves "incredible" response rates over 70% in heavily pretreated patients Dec 11, 2022
<ѻýҕl>Rigid In-Hospital Diet Offers No Advantage in Patients After HSCTѻýҕl> "We should eliminate these silly neutropenic diets," expert says Dec 10, 2022
<ѻýҕl>Lenalidomide-Induced Second Cancer Risk Limited to Multiple Myelomaѻýҕl> No increased risk to patients with other hematologic malignancies, meta-analysis shows Nov 02, 2022
<ѻýҕl>FDA Broadens Options for Relapsed/Refractory Multiple Myeloma With Teclistamabѻýҕl> Bispecific antibody achieved durable responses in a majority of heavily pretreated patients Oct 25, 2022
<ѻýҕl>Anti-BCMA-Based Regimen Impresses in Relapsed/Refractory Myelomaѻýҕl> Belamaf plus lenalidomide-dexamethasone achieved encouraging responses Sep 30, 2022
<ѻýҕl>'Unparalleled Times' in Hematology, but Workforce Issues Persistѻýҕl> "This is the most exciting time ever" to be a hematologist, says ASH President Jane Winter, MD Sep 26, 2022 video
<ѻýҕl>What's on Tap at the Society of Hematologic Oncology's 10th Annual Meetingѻýҕl> Emphasis on novel biological approaches in treating patients with hematologic malignancies Sep 26, 2022
<ѻýҕl>Bispecific Antibody Active in Heavily Treated Multiple Myelomaѻýҕl> Responses in 60% of patients who had received a median of five prior lines of therapy Aug 30, 2022
<ѻýҕl>Studies Reinforce Prognostic Role for Circulating Tumor Cells in Myelomaѻýҕl> At higher levels, different cutoffs show at least a doubling of PFS, OS hazard ratios Jun 13, 2022
<ѻýҕl>Myeloma Trial Supports 'Personalized Approach' to Upfront Transplantѻýҕl> DETERMINATION confirms benefit in triple-therapy setting, but suggests timing can be tailored Jun 06, 2022
<ѻýҕl>Unprecedented PFS Improvement in Relapsed Multiple Myelomaѻýҕl> Three-year median with addition of isatuximab to proteasome inhibitor backbone May 26, 2022
<ѻýҕl>Elotuzumab Combination Disappoints in Newly Diagnosed Myelomaѻýҕl> Study failed to replicate positive results seen in relapsed/refractory setting May 11, 2022
<ѻýҕl>Allo-Transplant With Omidubicel Hints at Longer-Term Benefits Tooѻýҕl> "Viable" option for patients eligible for umbilical cord blood transplantation, investigator says Apr 27, 2022
<ѻýҕl>Myeloma at Younger Age Shortens Lifespan Despite Lengthy Overall Survivalѻýҕl> Disease characteristics, prognostic factors similar to those of older patients Jan 04, 2022
<ѻýҕl>Induction Isatuximab-RVd Combo Boosts MRD Negativity in Multiple Myelomaѻýҕl> Half of newly diagnosed, transplant-eligible patients reached minimal residual disease negativity Dec 12, 2021
<ѻýҕl>Case of Parkinson's-Like Symptoms in Myeloma Patient After CAR-T Productѻýҕl> FDA advises monitoring patients after T-cell infusion for signs, symptoms of neurotoxicity Dec 10, 2021
<ѻýҕl>Is Multiple Myeloma a Greater Threat to Black Patients?ѻýҕl> Incidence and treatment disparities combined with a heightened COVID risk is cause for concern Nov 11, 2021
<ѻýҕl>Rare Case of Multiple Myeloma in Teenage Girlѻýҕl> Successful use of affordable induction therapy with autologous stem cell transplantation Nov 09, 2021
<ѻýҕl>Myeloma Drug Pulled From Market Just Months After Approvalѻýҕl> Data from confirmatory trial failed to make a compelling case for full FDA approval Oct 22, 2021
<ѻýҕl>No Survival Benefit With All-Oral Regimen for Relapsed/Refractory Myelomaѻýҕl> Prolonging PFS a positive, as advances make OS improvement harder to achieve Jun 18, 2021
<ѻýҕl>Charles Grodin's Death From Multiple Myelomaѻýҕl> A look at the beloved actor's highly treatable but rarely curable disease Jun 02, 2021
<ѻýҕl>Three-Drug Regimen Reduces Myeloma Treatment Burdenѻýҕl> Efficacy maintained with addition of SQ daratumumab to pomalidomide, dexamethasone Dec 04, 2020
<ѻýҕl>FDA OKs Anti-BCMA Drug for Multiple Myelomaѻýҕl> Accelerated approval for belantamab mafodotin after four other therapies Aug 06, 2020
<ѻýҕl>Cancer Immunotherapy Tied to Severe COVID-19 Outcomesѻýҕl> Nearly threefold increased risk of hospitalization, severe respiratory illness Jun 25, 2020
<ѻýҕl>New Standard for Relapsed/Refractory Multiple Myeloma?ѻýҕl> Triplet regimen significantly extended median PFS versus doublet in IKEMA study Jun 15, 2020
<ѻýҕl>High Marks for CAR T Cells in R/R Myelomaѻýҕl> Response rates of 70-100% with BCMA-targeted products for heavily treated disease Jun 03, 2020
<ѻýҕl>VRd Still Reigns in Newly Diagnosed Myelomaѻýҕl> KRd fails to prove superiority in head-to-head trial Jun 01, 2020
<ѻýҕl>COVID-19 Mortality Spikes in Patients With Lung, Blood Cancersѻýҕl> Those with metastatic disease also at special risk for poor outcomes Apr 28, 2020
<ѻýҕl>DOAC Works in Cancer-Related VTE, No Tradeoff in Bleedsѻýҕl> Apixaban monotherapy matches dalteparin in non-inferiority trial Mar 29, 2020
<ѻýҕl>Denosumab Use in Myeloma Soars for No Obvious Reasonѻýҕl> More expensive than competitor without being better, so why does it now have nearly half the market? Dec 12, 2019
<ѻýҕl>Serum Immune Markers May Predict Conversion From MGUS to Myelomaѻýҕl> Results could support annual blood tests and risk assessment for those with MGUS and its subtype, light-chain MGUS Jul 19, 2019
<ѻýҕl>Combination Regimen Extends PFS in Myelomaѻýҕl> Large benefit but relevance of comparator questioned Dec 04, 2018
<ѻýҕl>NCCN Refines MM Treatment Guidelinesѻýҕl> 'An attempt to help the clinician make better decisions,' expert says Mar 25, 2018
<ѻýҕl>Longer PFS in Myeloma with Add-On Daratumumabѻýҕl> Anti-CD38 drug boosts response to VMP regimen Dec 12, 2017